PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27412504-5	2016	Analyses performed in RRMS showed that fingolimod-induced disease remission is associated with a significant increase in Bregs, CD19+/BTLA+, and CD19+/BTLA+/IL-10+ B lymphocytes.	Fingolimod Hydrochloride	39-49	CD19 molecule	Homo sapiens	128-132	
33007647-12	2020	We found that while fingolimod reduced the proportions of naive CD19+ B cells, it significantly increased the proportions of these cells which migrated.	Fingolimod Hydrochloride	20-30	CD19 molecule	Homo sapiens	64-68	
30852478-6	2019	24 hours after oral administration of Fingolimod (0.5 mg), the circulating blood CD4 + T, CD8 + T, CD19 + B and CD56 + natural killer cells of the patients in the combined treatment group decreased steadily to varying degrees.	Fingolimod Hydrochloride	38-48	CD19 molecule	Homo sapiens	99-103	
27412504-5	2016	Analyses performed in RRMS showed that fingolimod-induced disease remission is associated with a significant increase in Bregs, CD19+/BTLA+, and CD19+/BTLA+/IL-10+ B lymphocytes.	Fingolimod Hydrochloride	39-49	CD19 molecule	Homo sapiens	145-149	
17717597-4	2007	Our data indicate that FTY720 induces apoptosis and impairs clonogenicity of imatinib/dasatinib-sensitive and -resistant p210/p190(BCR/ABL) myeloid and lymphoid cell lines and CML-BC(CD34+) and Ph1 ALL(CD34+/CD19+) progenitors but not of normal CD34+ and CD34+/CD19+ bone marrow cells.	Fingolimod Hydrochloride	23-29	CD19 molecule	Homo sapiens	208-212	
17717597-4	2007	Our data indicate that FTY720 induces apoptosis and impairs clonogenicity of imatinib/dasatinib-sensitive and -resistant p210/p190(BCR/ABL) myeloid and lymphoid cell lines and CML-BC(CD34+) and Ph1 ALL(CD34+/CD19+) progenitors but not of normal CD34+ and CD34+/CD19+ bone marrow cells.	Fingolimod Hydrochloride	23-29	CD19 molecule	Homo sapiens	261-265